Drugs /

mage-a3 peptide vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.

Clinical Trials

View Clinical Trials for mage-a3 peptide vaccine

Mage-a3 peptide vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mage-a3 peptide vaccine, 1 is phase 2 (1 open).

HLA-A*02 Positive is the most frequent biomarker inclusion criterion for mage-a3 peptide vaccine clinical trials.

Oral cavity squamous cell carcinoma is the most common disease being investigated in mage-a3 peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mage-A3 Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mage-a3 peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mage-a3, gl-0817, mage-a3 multipeptide vaccine gl-0817, gl-0817 vaccine, gl0817 vaccine
NCIT ID [1]:
C91710

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.